These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 24811963)

  • 1. Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study.
    Cursiefen C; Viaud E; Bock F; Geudelin B; Ferry A; Kadlecová P; Lévy M; Al Mahmood S; Colin S; Thorin E; Majo F; Frueh B; Wilhelm F; Meyer-Ter-Vehn T; Geerling G; Böhringer D; Reinhard T; Meller D; Pleyer U; Bachmann B; Seitz B
    Ophthalmology; 2014 Sep; 121(9):1683-92. PubMed ID: 24811963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.
    Cursiefen C; Bock F; Horn FK; Kruse FE; Seitz B; Borderie V; Früh B; Thiel MA; Wilhelm F; Geudelin B; Descohand I; Steuhl KP; Hahn A; Meller D
    Ophthalmology; 2009 Sep; 116(9):1630-7. PubMed ID: 19643487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Re: Cursiefen et al.: Aganirsen antisense oligonucleotide eye drops inhibit keratitis-induced corneal neovascularization and reduce need for transplantation: the I-CAN study (Ophthalmology 2014;121:1683-92).
    Rocha EM; Nominato LF; Reinach PS
    Ophthalmology; 2015 May; 122(5):e28. PubMed ID: 25919780
    [No Abstract]   [Full Text] [Related]  

  • 4. Antiangiogenic activity of aganirsen in nonhuman primate and rodent models of retinal neovascular disease after topical administration.
    Cloutier F; Lawrence M; Goody R; Lamoureux S; Al-Mahmood S; Colin S; Ferry A; Conduzorgues JP; Hadri A; Cursiefen C; Udaondo P; Viaud E; Thorin E; Chemtob S
    Invest Ophthalmol Vis Sci; 2012 Mar; 53(3):1195-203. PubMed ID: 22323484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Author reply: To PMID 24811963.
    Cursiefen C; Viaud E
    Ophthalmology; 2015 May; 122(5):e28-9. PubMed ID: 25919779
    [No Abstract]   [Full Text] [Related]  

  • 6. The antiangiogenic insulin receptor substrate-1 antisense oligonucleotide aganirsen impairs AU-rich mRNA stability by reducing 14-3-3β-tristetraprolin protein complex, reducing inflammation and psoriatic lesion size in patients.
    Colin S; Darné B; Kadi A; Ferry A; Favier M; Lesaffre C; Conduzorgues JP; Al-Mahmood S; Doss N
    J Pharmacol Exp Ther; 2014 Apr; 349(1):107-17. PubMed ID: 24504098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
    Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
    Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective, randomised, placebo-controlled, double-masked, three-armed, multicentre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG study: study protocol for a randomised controlled trial.
    Lorenz K; Scheller Y; Bell K; Grus F; Ponto KA; Bock F; Cursiefen C; Flach J; Gehring M; Peto T; Silva R; Tal Y; Pfeiffer N
    Trials; 2017 Mar; 18(1):128. PubMed ID: 28302155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term safety profile and efficacy of topical bevacizumab (Avastin) eye drops against corneal neovascularization.
    Koenig Y; Bock F; Horn F; Kruse F; Straub K; Cursiefen C
    Graefes Arch Clin Exp Ophthalmol; 2009 Oct; 247(10):1375-82. PubMed ID: 19415316
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial.
    Petsoglou C; Balaggan KS; Dart JK; Bunce C; Xing W; Ali RR; Tuft SJ
    Br J Ophthalmol; 2013 Jan; 97(1):28-32. PubMed ID: 23087419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drops for corneal neovascularization.
    Das M; Murthy S
    Ophthalmology; 2010 Oct; 117(10):2042; author reply 2042-3. PubMed ID: 20888488
    [No Abstract]   [Full Text] [Related]  

  • 12. High-dose topical bevacizumab for corneal neovascularization.
    Waisbourd M; Levinger E; Varssano D; Moisseiev E; Zayit-Soudri S; Barak A; Loewenstein A; Barequet I
    Pharmacology; 2013; 92(5-6):310-4. PubMed ID: 24335191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II Randomized, Double-Masked, Vehicle-Controlled Trial of Recombinant Human Nerve Growth Factor for Neurotrophic Keratitis.
    Bonini S; Lambiase A; Rama P; Sinigaglia F; Allegretti M; Chao W; Mantelli F;
    Ophthalmology; 2018 Sep; 125(9):1332-1343. PubMed ID: 29653858
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angioregressive pretreatment of mature corneal blood vessels before keratoplasty: fine-needle vessel coagulation combined with anti-VEGFs.
    Koenig Y; Bock F; Kruse FE; Stock K; Cursiefen C
    Cornea; 2012 Aug; 31(8):887-92. PubMed ID: 22362005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a 'first in man' phase I investigation.
    Kain H; Goldblum D; Geudelin B; Thorin E; Beglinger C
    Br J Clin Pharmacol; 2009 Aug; 68(2):169-73. PubMed ID: 19694734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perilimbal bevacizumab injection for interface neovascularization after deep anterior lamellar keratoplasty.
    Foroutan A; Fariba B; Pejman B; Mahmoud J; Khalil GF; Arash EA; Foroutan P
    Cornea; 2010 Nov; 29(11):1268-72. PubMed ID: 20802316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
    Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
    Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent in vivo antiangiogenic effects of GS-101 (5'-TATCCGGAGGGCTCGCCATGCTGCT-3'), an antisense oligonucleotide preventing the expression of insulin receptor substrate-1.
    Al-Mahmood S; Colin S; Farhat N; Thorin E; Steverlynck C; Chemtob S
    J Pharmacol Exp Ther; 2009 May; 329(2):496-504. PubMed ID: 19208899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical evaluation of pazopanib eye drops versus ranibizumab intravitreal injections in subjects with neovascular age-related macular degeneration.
    Csaky KG; Dugel PU; Pierce AJ; Fries MA; Kelly DS; Danis RP; Wurzelmann JI; Xu CF; Hossain M; Trivedi T
    Ophthalmology; 2015 Mar; 122(3):579-88. PubMed ID: 25432081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.